Galyan Bio

Galyan Bio is a preclinical-stage biotechnology company dedicated to developing next-generation small molecule therapies for neurodegenerative disorders, with a primary focus on Huntington's disease. The company's lead program, GLN-1001, targets the underlying cause of Huntington's by modulating the mutant Huntingtin protein to prevent neurodegeneration. By utilizing a novel approach to small molecule drug discovery, Galyan Bio aims to provide orally bioavailable treatments that can cross the blood-brain barrier more effectively than current biologic alternatives. The company is headquartered in the San Francisco Bay Area and is led by a team with extensive experience in neuroscience and drug development. Galyan Bio is currently advancing its lead candidate through IND-enabling studies to support future clinical trials.